Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Drug-selective Anesthetic Insensitivity of Zebrafish Lacking γ-Aminobutyric Acid Type A Receptor β3 Subunits.

Yang X, Jounaidi Y, Mukherjee K, Fantasia RJ, Liao EC, Yu B, Forman SA.

Anesthesiology. 2019 Dec;131(6):1276-1291. doi: 10.1097/ALN.0000000000002963.

PMID:
31567362
2.

Etomidate Effects on Desensitization and Deactivation of α4β3δ GABAA Receptors Inducibly Expressed in HEK293 TetR Cells.

Liao Y, Liu X, Jounaidi Y, Forman SA, Feng HJ.

J Pharmacol Exp Ther. 2019 Jan;368(1):100-105. doi: 10.1124/jpet.118.252403. Epub 2018 Nov 2.

3.

High-throughput Screening in Larval Zebrafish Identifies Novel Potent Sedative-hypnotics.

Yang X, Jounaidi Y, Dai JB, Marte-Oquendo F, Halpin ES, Brown LE, Trilles R, Xu W, Daigle R, Yu B, Schaus SE, Porco JA Jr, Forman SA.

Anesthesiology. 2018 Sep;129(3):459-476. doi: 10.1097/ALN.0000000000002281.

4.

High-level production and purification in a functional state of an extrasynaptic gamma-aminobutyric acid type A receptor containing α4β3δ subunits.

Zhou X, Desai R, Zhang Y, Stec WJ, Miller KW, Jounaidi Y.

PLoS One. 2018 Jan 19;13(1):e0191583. doi: 10.1371/journal.pone.0191583. eCollection 2018.

5.

Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells.

Jounaidi Y, Cotten JF, Miller KW, Forman SA.

Cancer Res. 2017 Nov 1;77(21):5938-5951. doi: 10.1158/0008-5472.CAN-17-1007. Epub 2017 Sep 15.

6.

General Anesthetic Binding Sites in Human α4β3δ γ-Aminobutyric Acid Type A Receptors (GABAARs).

Chiara DC, Jounaidi Y, Zhou X, Savechenkov PY, Bruzik KS, Miller KW, Cohen JB.

J Biol Chem. 2016 Dec 16;291(51):26529-26539. Epub 2016 Nov 7.

7.

Etomidate uniquely modulates the desensitization of recombinant α1β3δ GABA(A) receptors.

Liu K, Jounaidi Y, Forman SA, Feng HJ.

Neuroscience. 2015 Aug 6;300:307-13. doi: 10.1016/j.neuroscience.2015.05.051. Epub 2015 May 29.

8.

Etomidate produces similar allosteric modulation in α1β3δ and α1β3γ2L GABA(A) receptors.

Feng HJ, Jounaidi Y, Haburcak M, Yang X, Forman SA.

Br J Pharmacol. 2014 Feb;171(3):789-98. doi: 10.1111/bph.12507.

9.

Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas.

Mupparaju S, Hou H, Lariviere JP, Swartz H, Jounaidi Y, Khan N.

Oncol Rep. 2011 Jul;26(1):281-6. doi: 10.3892/or.2011.1268. Epub 2011 Apr 15.

10.

Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.

Doloff JC, Jounaidi Y, Waxman DJ.

Cancer Gene Ther. 2011 Mar;18(3):153-66. doi: 10.1038/cgt.2010.52. Epub 2010 Sep 24. Erratum in: Cancer Gene Ther. 2011 Mar;18(3):228. Jounaidi, Y [added].

11.
12.

Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions.

Doloff JC, Waxman DJ, Jounaidi Y.

Hum Gene Ther. 2008 Dec;19(12):1383-400. doi: 10.1089/hum.2008.056.

13.

Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model.

Chen CS, Jounaidi Y, Su T, Waxman DJ.

Cancer Gene Ther. 2007 Dec;14(12):935-44. Epub 2007 Sep 14.

14.

Conditionally replicating adenoviruses for cancer treatment.

Jounaidi Y, Doloff JC, Waxman DJ.

Curr Cancer Drug Targets. 2007 May;7(3):285-301. Review.

15.
16.

Cancer chemotherapy and drug metabolism.

Riddick DS, Lee C, Ramji S, Chinje EC, Cowen RL, Williams KJ, Patterson AV, Stratford IJ, Morrow CS, Townsend AJ, Jounaidi Y, Chen CS, Su T, Lu H, Schwartz PS, Waxman DJ.

Drug Metab Dispos. 2005 Aug;33(8):1083-96.

PMID:
16049130
17.

Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.

Chen CS, Jounaidi Y, Waxman DJ.

Drug Metab Dispos. 2005 Sep;33(9):1261-7. Epub 2005 May 26.

PMID:
15919850
19.

Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.

Baldwin A, Huang Z, Jounaidi Y, Waxman DJ.

Arch Biochem Biophys. 2003 Jan 1;409(1):197-206.

PMID:
12464259
20.

Cytochrome P450-based gene therapy for cancer treatment: from concept to the clinic.

Jounaidi Y.

Curr Drug Metab. 2002 Dec;3(6):609-22. Review.

PMID:
12369889
23.

Construction of p450-expressing tumor cell lines using retroviruses.

Hecht JE, Jounaidi Y, Waxman DJ.

Methods Mol Med. 2000;35:85-94. doi: 10.1385/1-59259-086-1:85.

PMID:
21390801
24.

Evidence for the presence of a functional pregnane X receptor response element in the CYP3A7 promoter gene.

Pascussi JM, Jounaidi Y, Drocourt L, Domergue J, Balabaud C, Maurel P, Vilarem MJ.

Biochem Biophys Res Commun. 1999 Jul 5;260(2):377-81.

PMID:
10403778
25.

Cytochrome P450-based cancer gene therapy: recent advances and future prospects.

Waxman DJ, Chen L, Hecht JE, Jounaidi Y.

Drug Metab Rev. 1999 May;31(2):503-22. Review.

PMID:
10335450
26.

Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.

Jounaidi Y, Hecht JE, Waxman DJ.

Cancer Res. 1998 Oct 1;58(19):4391-401.

27.

DNA adduct formation in primary mouse embryo cells induced by 7H-dibenzo[c,g]carbazole and its organ-specific carcinogenic derivatives.

Gábelová A, Périn-Roussel O, Jounaidi Y, Périn F.

Environ Mol Mutagen. 1997;30(1):56-64.

PMID:
9258330
28.

Role of the liver-enriched transcription factors C/EBP alpha and DBP in the expression of human CYP3A4 and CYP3A7.

Ourlin JC, Jounaïdi Y, Maurel P, Vilarem MJ.

J Hepatol. 1997;26 Suppl 2:54-62.

PMID:
9204410
29.

Induction of CYP1A1 gene by benzimidazole derivatives during Caco-2 cell differentiation. Evidence for an aryl-hydrocarbon receptor-mediated mechanism.

Daujat M, Charrasse S, Fabre I, Lesca P, Jounaïdi Y, Larroque C, Poellinger L, Maurel P.

Eur J Biochem. 1996 May 1;237(3):642-52.

30.

Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein?

Jounaïdi Y, Hyrailles V, Gervot L, Maurel P.

Biochem Biophys Res Commun. 1996 Apr 16;221(2):466-70.

PMID:
8619878
31.

Sequence of the 5'-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7.

Jounaïdi Y, Guzelian PS, Maurel P, Vilarem MJ.

Biochem Biophys Res Commun. 1994 Dec 30;205(3):1741-7.

PMID:
7811260
32.

Overexpression of a cytochrome P-450 of the 2a family (Cyp2a-5) in chemically induced hepatomas from female mice.

Jounaïdi Y, Bonfils C, Périn F, Negishi M, Lange R.

Eur J Biochem. 1994 Feb 1;219(3):791-8.

Supplemental Content

Loading ...
Support Center